{"paper_id":"d732fc87-788a-48b2-8ae3-b66621787112","body_text":"Literatur\nBarbieri, R.L.: Etiology and epidemiology of endometriosis Am. J. Obstet. Gynecol. 162, 565–567, 1990\nButtram, V.C. jr.: Evolution of the Revised American Fertility Society Classification of Endometriosis Fertil Steril 43, 347–350, 1985\nEvers, J.L.H.: The second-look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression Fertil Steril 47, 502–504, 1987\nBrown, J.B.: Gonadotropins In: Infertility. Male and Female, p. 359, Insler, V., Lunenfeld, B. (eds.) Edinburgh, Churchill Livindston 1986\nFraser, H.M., Sandow, J., Seidel, H., v.Rechenberg, W.: An implant of agonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3–5 month Acta Endocrinol (Copenh) 115, 521–527, 1987\nAuthor information\nAuthors and Affiliations\nRights and permissions\nAbout this article\nCite this article\nWiegratz, I., Dannhof, M., Baumann, R. et al. Die Behandlung der Endometriose mit einem langwirksamen, injizierbaren LH-RH-Analogon (Buserelin). Arch Gynecol Obstet 254, 592–594 (1993). https://doi.org/10.1007/BF02266112\nIssue date:\nDOI: https://doi.org/10.1007/BF02266112","source_license":"CC0","license_restricted":false}